What are ADC's

Our services

ADC Review
is made possible by:

NCT00962767 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission (NCT00962767)

Trial Description
The study will compare the efficacy of the 2 treatments in intermediate and high-risk APL patients in achieving first hematological complete remission and molecular remission.

This trial is sponsored by Pfizer/Wyeth-Ayerst Laboratories. [1]

Study Data

  • Condition: Acute Myelocytic Leukemia
  • Interventions:
    • Drugs used in this trial
  • Phase: III
  • Enrollment: 168
  • Start: May 2002
  • Completion: December 2007
  • Last verified: August 2009

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 23, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar